top of page

NovelStem Reports Third Quarter Results on Form 10-Q

Boca Raton, FL, November 14, 2022 – NovelStem International Corp. (OTC Pink: NSTM), a development-stage company focused on the stem cell-based technology platform developed by Israel-based NewStem Ltd., today filed its Form 10-Q for the third quarter ended September 30, 2022. NovelStem became an SEC reporting company following the October 2022 effectiveness of its Form 10 registration statement. NovelStem’s 10-Q filing is available here:

Please contact NovelStem’s IR team with any questions:

NovelStem Investor Relations

Bill Jones and David Collins

Catalyst IR

(212) 924-9800

About NovelStem International Corp.

NovelStem owns a 30.99% stake in NewStem Ltd. which is advancing its novel stem-cell-based diagnostic technology for predicting patients’ resistance to cancer therapies, allowing for better, targeted cancer treatments with the potential to reduce incidents of drug resistance. The technology is also being used for genetic research related to other medical needs.

About NewStem

NewStem Ltd., a biotechnology spinoff of Yissum, The Hebrew University of Jerusalem’s technology-transfer company, has established a bio-platform for genome wide screenings based on proprietary Haploid human Embryonic Stem Cell (HhESC) technology. These cells can potentially change the way we develop genetic based therapeutics and diagnostics, as they are superior to other cells used for whole genome screenings. NewStem is currently the only company worldwide to develop innovative practice-changing products based on this innovative and exclusive technology. NewStem utilizes this bio-platform for the discovery and development of precision oncology drugs based on synthetic lethal interaction modality and for diagnostics of anti-cancer drugs resistance. NewStem’s licensed technology is based on the research of Professor Nissim Benvenisty, Director of the Azrieli Center for Stem Cells and Genetic Research at the Hebrew University. NewStem holds the intellectual property, reagents and experience required for HhESC isolation, differentiation, genetic manipulation, immunogenicity and tumorigenicity.


bottom of page